A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.

Pfizer

Status: Completed

Conditions: COVID-19

Treatments: Drug: SoC; Other: Disease description

Study type: Observational

Funder types: Industry

Identifiers

NCT06085924

NCT06085924 (Registry Identifier)

C4671061

Details and patient eligibility

About

The purpose of this study is to learn about:

• effects of living with COVID-19 and
• how effective is nirmatrelvir-ritonavir in treating COVID-19.

This is a study of two groups of COVID-19 patients in Taiwan.

In Group 1 the below participants were included in the study:

• Patients of all ages.
• Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021.
• Cases of patients registered in the databases.

In Group 2 the below participants were included in the study:

• Participants who are 12 years or older.
• Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022.

Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.

The study will look at:

• the nature of Covid-19 disease.
• as well as the experiences of people receiving the nirmatrelvir-ritonavir.

This study will help to:

• understand what type of patients will need to be admitted to hospitals.
• see severe results due to COVID 19 infection.
• have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.

Enrollment: 8,252,912 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Cohort 1:

Inclusion Criteria:

• Patients of all ages
• Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
• Cases of patients registered in the databases

Exclusion Criteria:

• Patients without COVID-19 diagnosis

Cohort 2:

Inclusion Criteria:

• ≥12 years of age
• Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022

Exclusion Criteria:

• Patients without COVID-19 diagnosis

Trial design

8,252,912 participants in 2 patient groups

Cohort 1 - Cases of patients registered in the databases of all ages

Description:

Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021

Treatment:

Other: Disease description

Cohort 2 - Cases of patients registered in the databases of ≥12 years of age

Description:

Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022

Treatment:

Drug: SoC